B7-H3 SCLC
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer

Released: April 28, 2025

Expiration: October 27, 2025

Activity

Progress
1
Course Completed

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including:

  • Rationale for targeting B7-H3
  • Overview of the structure of antibody-drug conjugates (ADCs)
  • Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLC
  • Data from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLC
  • An overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLC
  • Early phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093